NCT01885208 · Interventional trial
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Overall registry status Completed
Phase 3
Conditions Diabetes, Diabetes Mellitus, Type 2
Delaware Valley sites
- Novo Nordisk Investigational Site · Lansdale, PA · Montgomery County
- Novo Nordisk Investigational Site · Norristown, PA · Montgomery County
First posted
Registry updated
Added to the directory